US-listed stock · Healthcare · Medicines including diabetes and obesity drugs · close 16 Nov 2026
Close
$1,431.67
Day change
-0.8%
1 month
+13.9%
6 months
+42.5%
1 year
+39.6%
3 years
+143.2%
5 years
+455.5%
From 52-week high
-0.8%
Weinstein stage
Stage 2
Eli Lilly closed at $1,431.67 on 16 Nov 2026. Over the past year it has gained 39.6%, and over five years +456% in all (+40.9% a year). It is 0.8% below its 52-week closing high of $1,443.50, set on 13 Nov 2026, and 68.2% above its 52-week closing low of $851.21. The price is above its 200-day average of $1,111.30 - an average that is itself still rising. On Stan Weinstein's stage analysis it is in Stage 2: advancing - above a rising 150-day average. Its deepest fall from a peak in the period shown was 35%.
Price, RSI and MACD
Price · +40.2% over the period
RSI (14) · 66.8
MACD (12, 26, 9) · histogram +1.67
Price · +39.6% over the period
RSI (14) · 66.8
MACD (12, 26, 9) · histogram +1.67
Price · +74.8% over the period
RSI (14) · 66.8
MACD (12, 26, 9) · histogram +1.67
Price · +139.5% over the period
RSI (14) · 66.8
MACD (12, 26, 9) · histogram +1.67
Price · +454.0% over the period
RSI (14) · 66.8
MACD (12, 26, 9) · histogram +1.67
Price: daily close adjusted for stock splits, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.
50-day average $1,246.72 · 200-day average $1,111.30 · 52-week closing range $851.21 – $1,443.50
Daily closes to 16 Nov 2026, adjusted for stock splits (not dividends), from Google Finance and Yahoo Finance. US stock prices in US dollars; index levels in points. Figures may be delayed and are for information only.
For research & education only — not investment advice or a recommendation to buy or sell any security. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by any exchange or index provider. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.